United States. Securities and Exchange Commission
Marvell Technology, Inc. announced the completion of exchange transactions with noteholders of Inphi Corporation, a wholly owned subsidiary of the company. The exchange, which was conducted on April 29, 2021, saw the delivery of 7,115,085 newly issued shares of Marvell's common stock to a limited number
United States. Securities and Exchange Commission
Cytokinetics, Incorporated has filed a FORM 8-K (Current Report) with the Securities and Exchange Commission regarding the termination of its License and Collaboration Agreement with Astellas Pharma Inc., effective November 1, 2021. The agreement, which was signed on April 23, 2020, granted Astellas exclusive rights to co-develop and commercialize skeletal
Cybernet Data Systems Inc.
Fifth Third Bancorp, a diversified financial services company headquartered in Cincinnati, Ohio, has announced that its subsidiary, Fifth Third Bank, National Association, will redeem two types of senior bank notes due July 26, 2021. The redemption notice was submitted to the issuing and paying agent on April 30, 2021, and
Information technology services industry
Stratus Properties Inc., a diversified real estate company, has announced the launch of Holden Hills, a new residential development in the desirable Barton Creek community. The project features 475 home sites, with a focus on design sustainability, renewable energy, and natural amenities. Stratus's Chairman, President, and Chief Executive
Information technology services industry
Dr. Hannah Valantine, a renowned pioneer in the field of clinical expansion and workforce diversity, has been nominated for election to Pacific Biosciences' Board of Directors as a Class II director at its 2021 Annual Meeting of Stockholders. Dr. Valantine's expertise and leadership in critical areas will
Cybernet Data Systems Inc.
Capri Holdings Limited, a leading luxury fashion company, has announced that its 2021 Annual Meeting of Shareholders will take place on Wednesday, July 28, 2021. The meeting will be held in accordance with the company's Memorandum and Articles of Association, as well as the rules and regulations of
United States. Securities and Exchange Commission
Advanced Micro Devices, Inc. has completed its merger with Xilinx, Inc., a leader in programmable logic devices. The merger was previously announced on October 26, 2020, and was subject to regulatory approvals and other closing conditions. The completion of the merger is a significant milestone for AMD, as it expands
United States. Securities and Exchange Commission
Cytokinetics, a late-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted orphan drug designation to CK-274, a next-generation cardiac myosin inhibitor, for the treatment of symptomatic hypertrophic cardiomyopathy (HCM). This designation provides Cytokinetics with benefits such as a seven-year period of U.S. marketing exclusivity
United States. Securities and Exchange Commission
On December 29, 2020, Tesla, Inc. and Panasonic Corporation of North America entered into a 2021 Pricing Agreement (Japan Cells) for the supply of lithium-ion battery cells by Panasonic in Japan. This agreement, effective from October 1, 2020, until March 31, 2022, is subject to the Supply Agreement between Tesla
United States. Securities and Exchange Commission
Xcel Energy's subsidiary, Southwestern Public Service Company (SPS), has filed an electric rate case with the New Mexico Public Regulation Commission (NMPRC) seeking an increase in base rates of approximately $88 million. This increase, primarily driven by additional capital investment in new and upgraded electric facilities and equipment,
United States. Securities and Exchange Commission
The Securities and Exchange Commission has voted to propose amendments to Securities Act Rule 701 and Form S-8, designed to modernize the framework for compensatory securities offerings in light of significant changes in the employment landscape. The proposed changes aim to provide workers with the opportunity to share in the
United States. Securities and Exchange Commission
Cytokinetics, Incorporated, a biopharmaceutical company focused on cardiovascular and pulmonary muscle contractility, has received written notice of termination from Amgen Inc. of their Collaboration and Option Agreement for the discovery, development, and commercialization of novel small molecule therapeutics, including omecamtiv mecarbil, a cardiac myosin activator. This termination, effective on May
